Cellyan Biotechnology Co., Ltd (HKPD)
- Sector
- Healthcare
- Industry
- Medical Distribution
- Last price
- $1.45
- As of
Kresmion compiles this page from HKPD's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Cellyan Biotechnology Co., Ltd (HKPD): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-21.
See the full HKPD dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for HKPD on one page. Preview it with sample data, then open it live with a free account.
Preview the HKPD dossierActive events for HKPD
No recent events on HKPD in the last 180 days.
FREE, NO ACCOUNT
Every event on HKPD, as it fires
New filings, 13F moves and cross asset events on HKPD land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, HKPD
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 20-FSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
Going concern statement
HKPD's 20-F filed Aug 7, 2026 states:
These factors raise substantial doubts about the Company's ability to continue as a going concern.
Read the 20-F on SEC EDGAR Every company with a going concern statement
More data on HKPD
HKPD mentioned in Kresmion daily briefs
HKPD against its peers
HKPD's operating margin of -11.2% ranks in the 69th percentile of 7 Medical Distribution sub-industry peers, fiscal periods ending between 2025-03-31 and 2025-12-31.
| Metric | HKPD | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 20.3M USD | 26.9M USD | 36 | 6 |
| Gross margin | 11.9% | 12.1% | 44 | 7 |
| Operating margin | -11.2% | -27.8% | 69 | 7 |
| Net margin | -0.1% | -40.6% | 81 | 7 |
| Return on equity | -0.5% | n/a | n/a | 4 |
Peers (7): MEDS, VNOV, YI, COSM, SNYRQ, FOCL, AHG. Left out: EXHI (no annual filing), GEGP (no annual filing), EMPG.D (no annual filing), EBOSY (no annual filing). Fiscal periods ending between 2025-03-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (HKPD: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in HKPD on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on HKPD in the last 180 days.
Upstream: SEC EDGAR filings for HKPD
Kresmion, "Cellyan Biotechnology Co., Ltd (HKPD) institutional holdings and SEC filings", data as of 2026-10-21, https://kresmion.com/research/HKPD. Upstream data: SEC EDGAR filings for HKPD.
Link to this data (HTML):
<a href="https://kresmion.com/research/HKPD">Cellyan Biotechnology Co., Ltd (HKPD) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow HKPD on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to HKPD for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.